Featuring a summary of the Open Pharma team’s trip to Evidence-Based Medicine Live 2019, the potential use of Literature Programming to improve research transparency, a new data depot project in India and the lack of institutional incentives for researchers to publish open access
Featuring the predatory market for fake science, the paywall surrounding Cabell’s blacklist and the success of medRxiv
Featuring concerns over predatory journals infiltrating PubMed, priorities for Plan S, new guidelines for open peer review and the first full open access agreement for Springer Nature
Featuring a new database of journal editorial policies, improvements in the perceived transparency and credibility of industry-sponsored research, an analysis of institutional open access, feedback on Plan S and an analysis of open access policies of leading medical journals.
Featuring the role of the scientific community in maximizing the impact of metadata, the value of plain-language summaries, an alternative open access publishing model and the growing support for Plan U
Featuring new methods for linking data sets to authors, the upcoming launch of medRxiv and a summary of the revised Plan S guidelines.
On 15 May 2019, the Center for Biomedical Research Transparency (CBMRT) brought the stakeholders in academic publishing together to share their varying perspectives on research transparency and accessibility at the European Biomedical Transparency Summit (BMTS), in Paris.
Featuring the rising tide of article processing charges and preprints, the changes to the ways in which journals are judged and the limited value of social media in increasing the reach of research
Featuring a summary of Scholastica’s interview with Stuart Taylor, revised feedback on Plan S from Springer Nature and the development of a community-led publisher
Featuring a fresh review of Cabell’s blacklist, increased article processing charges from two major publishers, the future of funding body journals and further support for open access from the European Commission